Proposal to list medical devices supplied by Culpan Distributors Ltd

Hospital devices Consultation Closed

PHARMAC is seeking feedback on a proposal to list a range of needles and syringes through a provisional agreement with Culpan Distributors Ltd.

What we’re proposing

PHARMAC is seeking feedback on a proposal to list a range of needles and syringes in Part III of Section H of the Pharmaceutical Schedule from 1 April 2019, through a provisional agreement with Culpan Distributors Ltd (“Culpan”).

Consultation closes at 4pm on Thursday, 13 February 2019 and feedback can be emailed to

What would the effect be?

From 1 April 2019, Culpan’s range of needles and syringes products would be listed under the proposed national agreement for all DHBs to purchase under, subject to consultation and approval by PHARMAC’s Board or delegate (“Agreement”).

This Agreement would not be for sole supply, with DHBs continuing to be able to purchase other suppliers’ brands of needles and syringes. The Agreement includes products that are new to DHB Hospitals and would provide a greater range of products for clinical staff to choose from.

The Agreement would supersede any existing DHB contracts with Culpan for the devices included in the Agreement. Any medical device listed in the Agreement and purchased by a DHB Hospital would be at the price, terms and conditions stated in the Agreement, effective from the date of listing on the Pharmaceutical Schedule.

As part of the Agreement, Culpan would provide educational services that would be tailored to the individual needs of DHB Hospitals, in formats and at times as required by DHB Hospitals.

Pricing for the devices in the Agreement, subject to any prior termination of the Agreement, would not be increased without prior consultation and approval by PHARMAC.

Who we think will be interested

  • Suppliers and Wholesalers
  • All DHB clinical staff including but not limited to:
    • Allied Health staff
    • Anaesthetists
    • Clinical engineers
    • Clinical staff working in surgical and medical units, emergency departments, intensive and critical care units, and outpatient units
    • District nurses
    • Perioperative staff
    • Procurement Officers
    • Oncologists
    • Radiologists
    • Technical staff
    • Urologists

About the medical devices

Needles and syringes

Needles and syringes are medical devices predominantly used to inject fluids (such as medicines) into or withdraw fluids from the body (such as blood). Syringes are also used for a variety of other purposes such as for flushing, irrigating and are also used with medical gases and air. These medical devices are used across a wide range of clinical settings.

Included in this proposal are a number of specialised needles used in biopsy, drainage and prostate seeding procedures.

Why we’re proposing this

In 2017 PHARMAC issued a Request for Proposals (“RFP”) for needles and syringes.

The RFP was for non-exclusive national agreements for listing in the Pharmaceutical Schedule.

PHARMAC has been working with suppliers to seek provisional agreements and this proposal is the latest to arise from this process. We expect to consult on further proposed agreements in this category over the coming months.

Details about our proposal

PHARMAC has entered into a provisional Agreement with Culpan for a range of needles and syringes. Pricing has been made available to appropriate DHB personnel.

The proposal would result in Pharmaceutical Schedule listings for 18 needle and syringe products.

Needles and syringes

  • Hawkins Blunt Needle Access System
  • Prostate stabilization needles
  • Prostate seeding sets
  • SKATER Centesis Needles and Catheters.

These products are manufactured by Argon Medical Devices

To provide feedback

Send us an email: by 4 pm 13 February 2019.

All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.